Sanofi (EPA:SAN) received a €93.00 ($114.81) price objective from equities research analysts at Deutsche Bank in a report released on Thursday. The firm presently has a “buy” rating on the stock. Deutsche Bank’s price objective points to a potential upside of 46.71% from the company’s current price.
SAN has been the subject of several other research reports. Berenberg Bank set a €97.00 ($119.75) target price on shares of Sanofi and gave the stock a “neutral” rating in a report on Monday, January 22nd. Morgan Stanley set a €92.00 ($113.58) price objective on shares of Sanofi and gave the stock a “buy” rating in a research report on Thursday, October 26th. Goldman Sachs Group set a €82.00 ($101.23) price objective on shares of Sanofi and gave the stock a “neutral” rating in a research report on Tuesday, October 17th. Barclays set a €65.00 ($80.25) price objective on shares of Sanofi and gave the stock a “sell” rating in a research report on Tuesday, January 23rd. Finally, UBS Group set a €82.00 ($101.23) target price on shares of Sanofi and gave the stock a “neutral” rating in a research report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of €84.63 ($104.48).
Shares of Sanofi (EPA:SAN) traded down €1.70 ($2.10) during trading hours on Thursday, hitting €63.39 ($78.26). 4,980,000 shares of the company’s stock were exchanged, compared to its average volume of 2,940,000. The stock has a market cap of $80,070.00 and a PE ratio of 20.99. Sanofi has a 1-year low of €63.09 ($77.89) and a 1-year high of €92.97 ($114.78).
TRADEMARK VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/11/deutsche-bank-reiterates-93-00-price-target-for-sanofi-san.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.